Experienced HIV Litigation Firm in Pittsburgh
For years, Gilead Sciences, Inc. sold dozens of antiretroviral HIV medications to the public, including a drug called Complera. Because it contains tenofovir disoproxal fumarate (TDF), a known toxin that can cause serious kidney and bone damage even at prescribed doses, Complera has put the lives of hundreds of HIV patients at risk across the country.
After Gilead Sciences was hit by a class action lawsuit in 2018, many other plaintiffs have come forward to claim HIV drug injuries as a result of using Complera. If you or someone you love has been affected by Complera injuries, don’t hesitate to contact our skilled Pittsburgh legal team at Robert Peirce & Associates, P.C. Bringing over 40 years of experience and a personalized approach, it’s our goal to help you recover maximum compensation to cover your medical costs, lost future wages, and other losses after suffering a life-altering injury.
Call (844) 383-0565 to schedule your free consultation today!
Delays and Defects at Gilead Sciences, Inc.
Tenofovir disoproxal fumarate (TDF) was first developed in the 1980s, and once the formula for this intravenous HIV medication was bought by Gilead Sciences, Inc., the company began to seek FDA approval for new orally-based medications. Gilead released the first TDF-based drug, Viread, in 2001 once the FDA had approved it in pill form.
Over the following 10 years, however, many patients reported experiencing severe side effects after taking Complera and other TDF medications. It was already known from an early point that TDF could cause decreased bone density in humans and animals. But documents from recent class action lawsuits demonstrate that Gilead knew that TDF could cause far more severe side effects – and purposely halted development on a safer replacement drug in order to maximize their profits.
Because TDF is technically a toxin, it’s difficult for human kidneys to absorb all of the chemical into the bloodstream, which can result in kidney failure and chronic kidney disorders with long-term use. Gilead’s less-toxic replacement HIV drug, known as tenofovir alafenamide fumarate (TAF), was finally released in 2016, after more than 10 years on the laboratory shelf pending further development.
The side effects of Complera may include:
- Chronic kidney disease
- Renal failure requiring dialysis
- Low kidney function requiring dialysis
- Low kidney function
- High creatinine levels
- Abnormal glomerular filtration rate
- Renal failure and hospitalizations
- Death due to renal failure
- Abnormal protein levels in the urine
- Fanconi syndrome/proximal renal tubule dysfunction
- Bone fractures or bone weakening
- Bone density loss, bone demineralization, or weakening of the bones
How Can I Seek Compensation?
The level of corporate negligence shown at Gilead Sciences, Inc. has led many AIDS organizations and individual plaintiffs to file lawsuits against the company. In these claims, the plaintiffs allege that Gilead knew TDF had serious design flaws, and yet did not attempt to develop the safer alternative for more than a decade. This is likely because the list price of Complera averaged at about $35,000 per year, allowing the company to benefit from a fundamentally defective product.
As a result of this negligence, many plaintiffs across the country are seeking damages for their reduced earning capacity, pain and suffering, and medical costs. While class action lawsuits are generally not ideal for those experiencing severe and life-altering injuries, our legal team can help you bring an individual product liability claim against the company and secure the financial resources you deserve. We handle a wide range of prescription drug claims, and we’re ready to fight on behalf of our client’s rights.
Contact us today by calling (844) 383-0565! We serve residents of Pittsburgh and surrounding areas.